Please login to read the full text of the article.
If you have no account yet, please register now.
Posted on
Previous Article
« Gender-based approach to MS therapeutics: a missed opportunity Next Article
Satralizumab lowers risk of severe relapse in NMOSD patients »
« Gender-based approach to MS therapeutics: a missed opportunity Next Article
Satralizumab lowers risk of severe relapse in NMOSD patients »
Table of Contents: MS Virtual 2020
Featured articles
COVID-19 and MS
Biomarkers
Treatment Strategies and Results
Management of progressive MS with approved DMT
Novel Treatment Directions
Neuromyelitis Optica Spectrum Disorders
Miscellaneous Topics
Related Articles
December 9, 2021
WNT9B-gene variant associated with doubled relapse risk in MS
September 10, 2020
Fampridine treatment results in routine clinical practice
© 2021 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy